A PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE DOSE OF IPN10200 IN THE IMPROVEMENT OF MODERATE TO SEVERE GLABELLAR LINES IN ADULT PARTICIPANTS

Registry ID
CLIN-10200-459
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
IPSEN BIOPHARMACEUTICALS INC
Start date
2026-03-26
Last update
2026-03-04

Conditions

Related clinical trials

View on source registry